Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease, hypertension, insulin resistance, and diabetic nephropathy. The company is headquartered in Vancouver, Canada.
52W High
$2.51
52W Low
$0.66
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.05
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
0.96
EV/EBITDA (<8 favorable)
0.09
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
2.12
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
2.63%
Institutions (25–75% balanced)
4.64%
Shares Outstanding
5,212,200
Float
5,069,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.46
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.79%
EPS YoY (Quarterly) (>10% good)
-0.97
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
0.0017
Previous
0.0013
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025